EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Update on the Discovery of Efflux Pump Inhibitors against Critical Priority Gram-Negative Bacteria

Nina Compagne, Anais Vieira Da Cruz, Reinke T Müller, Ruben C Hartkoorn iD, Marion Flipo iD, Klaas M Pos iD

Antibiotics · 15.01.2023 · 12 (1) · 180

DOI: 10.3390/antibiotics12010180 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 15.01.2023. Verfasst von Nina Compagne und 5 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille, Inserm, Institut Pasteur de Lille, U1177-Drugs and Molecules for Living Systems, F-59000 Lille, France. Die Arbeit wurde bisher 116-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: l’Agence Nationale de la Recherche (ANR, France) in partnership with the Bundesministerium für Bildung und Forschung (BMBF, Germany).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antimicrobial resistance (AMR) has become a major problem in public health leading to an estimated 4.95 million deaths in 2019. The selective pressure caused by the massive and repeated use of antibiotics has led to bacterial strains that are partially or even entirely resistant to known antibiotics. AMR is caused by several mechanisms, among which the (over)expression of multidrug efflux pumps plays a central role. Multidrug efflux pumps are transmembrane transporters, naturally expressed by Gram-negative bacteria, able to extrude and confer resistance to several classes of antibiotics. Targeting them would be an effective way to revive various options for treatment. Many efflux pump inhibitors (EPIs) have been described in the literature; however, none of them have entered clinical trials to date. This review presents eight families of EPIs active against Escherichia coli or Pseudomonas aeruginosa. Structure–activity relationships, chemical synthesis, in vitro and in vivo activities, and pharmacological properties are reported. Their binding sites and their mechanisms of action are also analyzed comparatively.

Schlagwörter

Stichwörter der Autor:innen

AcrBGram-negative bacteriaMexBRND multidrug efflux pumpantibiotic resistance breakersantimicrobial resistanceefflux pump inhibitor

Autor:innen und Institutionen

  • Univ. Lille, Inserm, Institut Pasteur de Lille, U1177-Drugs and Molecules for Living Systems, F-59000 Lille, France.
  • Institute of Biochemistry, Goethe-University Frankfurt, Max-von-Laue-Str. 9, D-60438 Frankfurt am Main, Germany.
  • Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France.

ORCID-Profile: Ruben C Hartkoorn, Marion Flipo, Klaas M Pos

Förderung

  • l’Agence Nationale de la Recherche (ANR, France) in partnership with the Bundesministerium für Bildung und Forschung (BMBF, Germany)

Zitieren

APA

Compagne, N., Vieira Da Cruz, A., Müller, R. T., Hartkoorn, R. C., Flipo, M., & Pos, K. M. (2023). Update on the Discovery of Efflux Pump Inhibitors against Critical Priority Gram-Negative Bacteria. Antibiotics, 12(1), 180. https://doi.org/10.3390/antibiotics12010180

Vancouver

Compagne N, Vieira Da Cruz A, Müller RT, Hartkoorn RC, Flipo M, Pos KM. Update on the Discovery of Efflux Pump Inhibitors against Critical Priority Gram-Negative Bacteria. Antibiotics. 2023;12(1):180. doi:10.3390/antibiotics12010180

BibTeX
@article{Compagne2023,
  author = {Compagne, Nina and Vieira Da Cruz, Anais and Müller, Reinke T and Hartkoorn, Ruben C and Flipo, Marion and Pos, Klaas M},
  title = {Update on the Discovery of Efflux Pump Inhibitors against Critical Priority Gram-Negative Bacteria},
  journal = {Antibiotics},
  year = {2023},
  volume = {12},
  number = {1},
  pages = {180},
  doi = {10.3390/antibiotics12010180}
}
Kostenlos starten →